Fiscal year 2025 executive and director compensation, incentive-plan design, equity activity, and governance — every figure in this brief is traceable to its exact location in the company’s SEC filing — the document, the section, the page, and the table, linked directly.
Each company listed discloses GPCR in its own benchmarking peer group, as disclosed in each company's most recent proxy statement within the last two proxy seasons. Two companies are therefore absent by design: one that named GPCR in an earlier year and no longer does, and one whose own most recent disclosure is older than the last two seasons.
| Named executive officer | Salary | Bonus | Stock awards | Option awards | Non-equity incentive | Pension / NQDC | All other | Total |
|---|---|---|---|---|---|---|---|---|
| Raymond Stevens | $672,094 | $0 | $2,387,996 | $4,846,926 | $508,871 | $0 | $14,000 | $8,429,887 |
| Chief Executive Officer and Director | ||||||||
| Jun Yoon | 530,530 | 0 | 1,193,998 | 2,423,463 | 309,075 | 0 | 10,529 | 4,467,595 |
| Chief Financial Officer | ||||||||
| Blai Coll | 492,813 | 0 | 820,866 | 1,666,117 | 253,151 | 0 | 14,000 | 3,246,947 |
| Chief Medical Officer | ||||||||
| Xichen Lin | 505,313 | 0 | 567,150 | 1,151,143 | 257,103 | 0 | 0 | 2,480,709 |
| Chief Scientific Officer | ||||||||
| Yingli Ma | 429,768 | 0 | 447,734 | 908,788 | 212,592 | 0 | 0 | 1,998,882 |
| Chief Technology Officer | ||||||||
A dash means the company reported no figure in that column; 0 means it reported zero. Figures are as printed in the filing, without adjustment.
| Named executive officer | FY2025 total | FY2024 total | FY2023 total | Δ FY2024→2025 |
|---|---|---|---|---|
| Raymond Stevens | $8,429,887 | — | — | — |
| Jun Yoon | 4,467,595 | — | — | — |
| Blai Coll | 3,246,947 | — | — | — |
| Xichen Lin | 2,480,709 | — | — | — |
| Yingli Ma | 1,998,882 | — | — | — |
Prior-year totals as disclosed in the corresponding proxy; deltas are computed values with the derivation shown in the register.
Every insider equity transaction reported on Form 4 after the 2025 proxy statement — acquisitions, dispositions, exercises, and withholdings — and therefore not reflected in any table in that document.
| Insider | Role | Transaction date | Code | Shares | Price | Value | Security | Source |
|---|---|---|---|---|---|---|---|---|
| Daniel G. Welch | Director | 2026-06-17 | A | 39,453 | $0 | $0 | Derivative, Class A Common | Form 4 ↗ |
| Ted W. Love | Director | 2026-06-17 | A | 39,453 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Angus C. Russell | Director | 2026-06-17 | A | 39,453 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Joanne Waldstreicher | Director | 2026-06-17 | A | 39,453 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Sharon Tetlow | Director | 2026-06-17 | A | 39,453 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Eric Dobmeier | Director | 2026-06-17 | A | 39,453 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Xichen Lin | CHIEF SCIENTIFIC OFFICER | 2026-06-25 | A | 23,634 | 0 | 8,036 | Common | Form 4 ↗ |
| Xichen Lin | CHIEF SCIENTIFIC OFFICER | 2026-06-25 | D | 23,634 | 0 | 0 | Common | Form 4 ↗ |
| Xichen Lin | CHIEF SCIENTIFIC OFFICER | 2026-06-25 | A | 7,878 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Xichen Lin | CHIEF SCIENTIFIC OFFICER | 2026-06-25 | D | 7,878 | 49 | 386,646 | Derivative, Class A Common | Form 4 ↗ |
| Xichen Lin | CHIEF SCIENTIFIC OFFICER | 2026-06-25 | D | 23,634 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Xichen Lin | CHIEF SCIENTIFIC OFFICER | 2026-07-14 | A | 23,634 | 0 | 8,036 | Common | Form 4 ↗ |
| Xichen Lin | CHIEF SCIENTIFIC OFFICER | 2026-07-14 | D | 6,278 | 51 | 318,895 | Derivative, Class A Common | Form 4 ↗ |
| Xichen Lin | CHIEF SCIENTIFIC OFFICER | 2026-07-14 | D | 1,600 | 52 | 82,734 | Derivative, Class A Common | Form 4 ↗ |
| Xichen Lin | CHIEF SCIENTIFIC OFFICER | 2026-07-14 | A | 7,878 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Xichen Lin | CHIEF SCIENTIFIC OFFICER | 2026-07-14 | D | 23,634 | 0 | 0 | Common | Form 4 ↗ |
| Xichen Lin | CHIEF SCIENTIFIC OFFICER | 2026-07-14 | D | 23,634 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| FMR LLC | Greater-than-10% holder | 2026-07-22 | D | 16,085 | 50 | 805,376 | Derivative, Class A Common | Form 4 ↗ |
| FMR LLC | Greater-than-10% holder | 2026-07-22 | D | 1,367 | 50 | 68,446 | Derivative, Class A Common | Form 4 ↗ |
Transaction codes per Form 4: A acquisition · S open-market sale · F tax withholding · M option exercise · G gift. Value = shares × price as reported. Dividend-equivalent and fractional-share accrual rows (derivative Class A, under $10,000 and under 2,000 shares) are aggregated per date; every row appears in full below.
| Executive | Award | Grant date | Threshold | Target | Granted | Maximum | Grant-date fair value |
|---|---|---|---|---|---|---|---|
| Jun Yoon | RSU | 2025-03-15 | — | — | 170,166 | — | $1,193,998 |
| Xichen Lin | RSU | 2025-03-15 | — | — | 80,829 | — | 567,150 |
| Raymond Stevens | RSU | 2025-03-15 | — | — | 340,332 | — | 2,387,996 |
| Jun Yoon | OPTION | 2025-03-15 | — | — | 413,445 | — | 2,423,463 |
| Xichen Lin | OPTION | 2025-03-15 | — | — | 196,386 | — | 1,151,143 |
| Blai Coll | OPTION | 2025-03-15 | — | — | 284,241 | — | 1,666,117 |
| Blai Coll | RSU | 2025-03-15 | — | — | 116,988 | — | 820,866 |
| Raymond Stevens | OPTION | 2025-03-15 | — | — | 826,890 | — | 4,846,926 |
| Named executive officer | Time-vested (RSU) | Performance-vested (PSU) | Options / SARs | % performance-vested |
|---|---|---|---|---|
| Jun Yoon | $1,193,998 | $0 | $2,423,463 | 0.0% |
| Xichen Lin | 567,150 | 0 | 1,151,143 | 0.0% |
| Raymond Stevens | 2,387,996 | 0 | 4,846,926 | 0.0% |
| Blai Coll | 820,866 | 0 | 1,666,117 | 0.0% |
% performance-vested = PSU grant-date fair value ÷ (RSU + PSU + Options), a computed value with the derivation shown in the register.
| Executive | Award | Shares unvested | Exercise price | Market value unvested |
|---|---|---|---|---|
| Xichen Lin | Option | 100,000 | 1.21 | — |
| Xichen Lin | RSU | 28,539 | — | 661,629 |
| Jun Yoon | RSU | 116,988 | — | 2,712,172 |
| Yingli Ma | RSU | 12,231 | — | 283,555 |
| Xichen Lin | Option | 120,087 | 11.75 | — |
| Jun Yoon | RSU | 9,000 | — | 208,650 |
| Xichen Lin | RSU | 49,965 | — | 1,158,355 |
| Raymond Stevens | RSU | 78,516 | — | 1,820,263 |
| Yingli Ma | Option | 155,040 | 7.02 | — |
| Raymond Stevens | RSU | 101,013 | — | 2,341,818 |
| Xichen Lin | RSU | 80,829 | — | 1,873,886 |
| Xichen Lin | RSU | 64,281 | — | 1,490,248 |
| Jun Yoon | Option | 83,328 | 11.75 | — |
| Yingli Ma | RSU | 63,810 | — | 1,479,329 |
| Jun Yoon | RSU | 19,803 | — | 459,100 |
| Jun Yoon | RSU | 170,166 | — | 3,945,015 |
| Jun Yoon | Option | 31,275 | 7.66 | — |
| Jun Yoon | RSU | 34,668 | — | 803,720 |
| Yingli Ma | RSU | 27,549 | — | 638,678 |
| Yingli Ma | RSU | 21,408 | — | 496,309 |
| Jun Yoon | RSU | 26,646 | — | 617,743 |
| Jun Yoon | RSU | 3,996 | — | 92,641 |
| Raymond Stevens | Option | 826,890 | 7.02 | — |
| Jun Yoon | Option | 218,775 | 5 | — |
| Raymond Stevens | Option | 466,687 | 5 | — |
| Yingli Ma | Option | 400,000 | 2.6 | — |
| Jun Yoon | Option | 284,241 | 7.02 | — |
| Xichen Lin | Option | 196,386 | 7.02 | — |
| Raymond Stevens | Option | 188,712 | 11.75 | — |
| Jun Yoon | Option | 100,000 | 1.21 | — |
| Jun Yoon | Option | 76,314 | 12.75 | — |
| Yingli Ma | Option | 51,468 | 11.75 | — |
| Jun Yoon | Option | 18,564 | 11.75 | — |
| Jun Yoon | Option | 5,760 | 2.79 | — |
| Jun Yoon | RSU | 67,950 | — | 1,575,308 |
| Jun Yoon | Option | 413,445 | 7.02 | — |
| Raymond Stevens | RSU | 340,332 | — | 7,890,030 |
| Raymond Stevens | RSU | 44,850 | — | 1,039,773 |
| Jun Yoon | RSU | 44,604 | — | 1,034,069 |
In designing our executive compensation program, the Compensation Committee and the Board are guided by the following philosophy and objectives: Attract and Retain Talent: Deliver competitive compensation at levels that attract, motivate and retain talented executives who contribute to the success of our business; Pay for Performance: Award compensation that motivates and rewards short- and long-term individual and company performance while discouraging excessive risk-taking; Alignment with Strategy: Provide incentives that motivate and reward the achievement of performance goals that directly correlate to the execution of our strategy and the enhancement of shareholder value, as well as to facilitate executive retention; and Alignment with Shareholders: Align our NEOs interests with those of our shareholders.
| CEO STI target (% of salary) | 60% |
|---|---|
| CEO LTI target (% of salary) | — |
| Independent consultant | Aon |
| Clawback policy | True |
| Anti-hedging | True |
| Anti-pledging | True |
| Meeting year | Meeting date | For | Against | Abstain | Support | Outcome |
|---|---|---|---|---|---|---|
| 2026 | 2026-06-17 | 158,547,441 | 6,187,647 | 212,691 | 96.24% | Passed |
| 2025 | 2025-06-23 | 115,026,066 | 19,231,338 | 101,028 | 85.68% | Passed |
Rows are labeled by annual-meeting year, with the meeting date beside each; the vote held in a given year acts on the prior fiscal year's compensation.
| Meeting year | Meeting date | Approval — company's computation |
|---|---|---|
| 2026 | 2026-06-17 | 96.24%a |
| 2025 | 2025-06-23 | 85.68%b |
a. Approved under the standard stated in the filing — “Abstentions will be counted for the purpose of determining the presence or absence of a quorum, but will not be counted for the purpose of determining the number of votes cast on a given proposal.”.
b. Approved under the standard stated in the filing — “If final voting results are not available to us in time to file a Form 8-K within four business days after the Annual General Meeting, we intend to file a Form 8-K t Abstentions will be counted for the purpose of determining the presence or absence of a quorum, but will not be counted for the purpose of determining the number of votes cast on a given proposal.”.
Approval percentages are the company's own reported computations under its own stated standard, not recomputed by Velarion. Where a company does not state a standard, none is assumed.
| Ratio (CEO : median employee) | 29 : 1 |
|---|---|
| CEO total compensation | $8,429,887 |
| Median employee compensation | $293,807 |
| Director | Cash fees | Stock awards | Option awards | Non-equity incentive | All other | Total |
|---|---|---|---|---|---|---|
| Daniel G. WelchIndependent · Board Chair · Compensation · Nominating and Corporate Governance (Chair) | $241,500 | $0 | $290,025 | $0 | $0 | $531,525 |
| Sharon TetlowIndependent · Audit (Chair) · Nominating and Corporate Governance | 70,000 | 0 | 290,025 | 0 | 0 | 360,025 |
| Ted W. Love, M.DIndependent · Compensation (Chair) · Research & Development | 67,500 | 0 | 290,025 | 0 | 0 | 357,525 |
| Joanne Waldstreicher, M.DIndependent · Nominating and Corporate Governance · Research & Development (Chair) | 65,000 | 0 | 290,025 | 0 | 0 | 355,025 |
| Eric DobmeierIndependent · Audit · Compensation | 62,500 | 0 | 290,025 | 0 | 0 | 352,525 |
| Angus C. RussellIndependent · Audit | 55,000 | 0 | 239,806 | 0 | 0 | 294,806 |
| Raymond Stevens, Ph.DEmployee director · Research & Development | 0 | 0 | 0 | — | 0 | 0 |
| Annual cash retainer | $45,000 |
|---|---|
| Annual equity retainer | $290,025 |
| Per board meeting fee | — |
| Committee chair fees (audit / comp / nom-gov) | 10,000 / 10,000 |
| Stock ownership guideline | — |
| Component | FY2025 |
|---|---|
| Cash retainers and fees | $561,500 |
| Equity awards (grant-date value) | $0 |
| All other compensation | $0 |
| Total cost of the board | $561,500 |
Computed as the sum of the director compensation table rows above; inputs and formula shown in the register.
The compensation peer group as the company disclosed it in its own proxy — the reference set behind the percentile above.
Of the companies Structure Therapeutics names as compensation peers, which name it back in their own disclosed peer groups. A peer set the market reciprocates reads differently from one selected in a single direction.
Reciprocity shown where the peer's own current proxy has been read — each mark is cited in the register to that peer's filing. A dash means the peer's current proxy was read and names no reciprocal group including Structure Therapeutics.
Most recent fiscal-year chief executive compensation at each disclosed peer, taken from that company's own proxy statement.
| Rank | Company | FY | Chief executive | Salary | Stock awards | Option awards | Non-equity incentive | Total |
|---|---|---|---|---|---|---|---|---|
| 1 | Element | 2025 | Benjamin H. Gliklich | $1,087,500 | $23,688,894 | $0 | $1,520,947 | $26,480,462 |
| 2 | Structure Therapeutics | 2025 | Raymond Stevens | 672,094 | 2,387,996 | 4,846,926 | 508,871 | 8,429,887 |
Each peer's compensation is from its most recently filed proxy; fiscal years differ by company. Each peer's figures come from its own filings; the subject company is highlighted. Peers whose chief executive compensation is outside our coverage universe are stated as such, never left blank.
| Company | Annual incentive payout | Long-term vehicle mix | PSU measures include TSR | Compensation consultant |
|---|---|---|---|---|
| Structure Therapeutics | 125% | Options 67 · RSU 33 | No | Aon |
| Element | 126% | PSU 67 · RSU 33 | No | FW Cook |
Read from each company's Compensation Discussion and Analysis: annual incentive payout as a percentage of target, the disclosed long-term vehicle mix, whether performance-share measures include a total shareholder return component, and the retained compensation consultant. “Not disclosed” appears only where the company's filing does not state the item.
Each figure's location is given both for the eye (section · page · table · row · column) and for a script (table/row/column index and exact character span in the filed document). Any figure can be independently confirmed against the source.
| # | Supports | Document | Filed | Accession | Location in document |
|---|---|---|---|---|---|
| 1 | Section 01, Raymond Stevens | DEF 14A | 2026-04-23 | 0001104659-26-047740 | Section “Summary Compensation Table”. As printed: 8,429,887. Filing ↗machine: r1 · c47 · span 552927–552936 |
| 2 | Section 01, Jun Yoon | DEF 14A | 2026-04-23 | 0001104659-26-047740 | Section “Summary Compensation Table”. As printed: 4,467,595. Filing ↗machine: r4 · c47 · span 566755–566764 |
| 3 | Section 01, Blai Coll | DEF 14A | 2026-04-23 | 0001104659-26-047740 | Section “Summary Compensation Table”. As printed: 3,246,947. Filing ↗machine: r7 · c47 · span 580652–580661 |
| 4 | Section 01, Xichen Lin | DEF 14A | 2026-04-23 | 0001104659-26-047740 | Section “Summary Compensation Table”. As printed: 2,480,709. Filing ↗machine: r9 · c47 · span 590245–590254 |
| 5 | Section 01, Yingli Ma | DEF 14A | 2026-04-23 | 0001104659-26-047740 | Section “Summary Compensation Table”. As printed: 1,998,882. Filing ↗machine: r11 · c47 · span 599544–599553 |
| 6 | Section 03, Jun Yoon RSU | DEF 14A | 2026-04-23 | 0001104659-26-047740 | Section “Grants of Plan-Based Awards” · grants of plan-based awards table. Filing ↗machine: t21 · r5 · c45 · span 637530–637539 |
| 7 | Section 03, Xichen Lin RSU | DEF 14A | 2026-04-23 | 0001104659-26-047740 | Section “Grants of Plan-Based Awards” · grants of plan-based awards table. Filing ↗machine: t21 · r11 · c45 · span 664433–664440 |
| 8 | Section 03, Raymond Stevens RSU | DEF 14A | 2026-04-23 | 0001104659-26-047740 | Section “Grants of Plan-Based Awards” · grants of plan-based awards table. Filing ↗machine: t21 · r2 · c45 · span 624101–624110 |
| 9 | Section 03, Jun Yoon OPTION | DEF 14A | 2026-04-23 | 0001104659-26-047740 | Section “Grants of Plan-Based Awards” · grants of plan-based awards table. Filing ↗machine: t21 · r6 · c45 · span 641844–641853 |
| 10 | Section 03, Xichen Lin OPTION | DEF 14A | 2026-04-23 | 0001104659-26-047740 | Section “Grants of Plan-Based Awards” · grants of plan-based awards table. Filing ↗machine: t21 · r12 · c45 · span 668745–668754 |
| 11 | Section 03, Blai Coll OPTION | DEF 14A | 2026-04-23 | 0001104659-26-047740 | Section “Grants of Plan-Based Awards” · grants of plan-based awards table. Filing ↗machine: t21 · r9 · c45 · span 655335–655344 |
| 12 | Section 03, Blai Coll RSU | DEF 14A | 2026-04-23 | 0001104659-26-047740 | Section “Grants of Plan-Based Awards” · grants of plan-based awards table. Filing ↗machine: t21 · r8 · c45 · span 650998–651005 |
| 13 | Section 03, Raymond Stevens OPTION | DEF 14A | 2026-04-23 | 0001104659-26-047740 | Section “Grants of Plan-Based Awards” · grants of plan-based awards table. Filing ↗machine: t21 · r3 · c45 · span 628440–628449 |
| 14 | Section 07, pay ratio | DEF 14A | 2026-04-23 | 0001104659-26-047740 | Section “CEO Pay Ratio”. As printed: 29 : 1. Filing ↗machine: span 980663–980665 |
| 15 | Section 08, Daniel G. Welch | DEF 14A | 2026-04-23 | 0001104659-26-047740 | Section “Director Compensation”. As printed: 531,525. Filing ↗machine: t30 · r5 · c17 · span 1068679–1068686 |
| 16 | Section 08, Sharon Tetlow | DEF 14A | 2026-04-23 | 0001104659-26-047740 | Section “Director Compensation”. As printed: 360,025. Filing ↗machine: t30 · r3 · c17 · span 1064484–1064491 |
| 17 | Section 08, Ted W. Love, M.D | DEF 14A | 2026-04-23 | 0001104659-26-047740 | Section “Director Compensation”. As printed: 357,525. Filing ↗machine: t30 · r2 · c17 · span 1062382–1062389 |
| 18 | Section 08, Joanne Waldstreicher, M.D | DEF 14A | 2026-04-23 | 0001104659-26-047740 | Section “Director Compensation”. As printed: 355,025. Filing ↗machine: t30 · r4 · c17 · span 1066574–1066581 |
| 19 | Section 08, Eric Dobmeier | DEF 14A | 2026-04-23 | 0001104659-26-047740 | Section “Director Compensation”. As printed: 352,525. Filing ↗machine: t30 · r1 · c17 · span 1060301–1060308 |
| 20 | Section 08, Angus C. Russell | DEF 14A | 2026-04-23 | 0001104659-26-047740 | Section “Director Compensation”. As printed: 294,806. Filing ↗machine: t30 · r6 · c17 · span 1070855–1070862 |
| 21 | Section 08, Raymond Stevens, Ph.D | DEF 14A | 2026-04-23 | 0001104659-26-047740 | Section “Director Compensation”. As printed: 0. Filing ↗ |
| 22 | Section 02, Daniel G. Welch 2026-06-17 | Form 4 | 2026-06-18 | 0001206199-26-000002 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 23 | Section 02, Ted W. Love 2026-06-17 | Form 4 | 2026-06-18 | 0001188919-26-000010 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 24 | Section 02, Angus C. Russell 2026-06-17 | Form 4 | 2026-06-18 | 0001534002-26-000002 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 25 | Section 02, Joanne Waldstreicher 2026-06-17 | Form 4 | 2026-06-18 | 0001962413-26-000002 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 26 | Section 02, Sharon Tetlow 2026-06-17 | Form 4 | 2026-06-18 | 0001328565-26-000002 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 27 | Section 02, Eric Dobmeier 2026-06-17 | Form 4 | 2026-06-18 | 0001202785-26-000004 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 28 | Section 02, Xichen Lin 2026-06-25 | Form 4 | 2026-06-29 | 0001962926-26-000005 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 29 | Section 02, Xichen Lin 2026-06-25 | Form 4 | 2026-06-29 | 0001962926-26-000005 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 30 | Section 02, Xichen Lin 2026-06-25 | Form 4 | 2026-06-29 | 0001962926-26-000005 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 31 | Section 02, Xichen Lin 2026-06-25 | Form 4 | 2026-06-29 | 0001962926-26-000005 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 32 | Section 02, Xichen Lin 2026-06-25 | Form 4 | 2026-06-29 | 0001962926-26-000005 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 33 | Section 02, Xichen Lin 2026-07-14 | Form 4 | 2026-07-15 | 0001962926-26-000006 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 34 | Section 02, Xichen Lin 2026-07-14 | Form 4 | 2026-07-15 | 0001962926-26-000006 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 35 | Section 02, Xichen Lin 2026-07-14 | Form 4 | 2026-07-15 | 0001962926-26-000006 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 36 | Section 02, Xichen Lin 2026-07-14 | Form 4 | 2026-07-15 | 0001962926-26-000006 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 37 | Section 02, Xichen Lin 2026-07-14 | Form 4 | 2026-07-15 | 0001962926-26-000006 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 38 | Section 02, Xichen Lin 2026-07-14 | Form 4 | 2026-07-15 | 0001962926-26-000006 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 39 | Section 02, FMR LLC 2026-07-22 | Form 4 | 2026-07-24 | 0001193125-26-315240 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 40 | Section 02, FMR LLC 2026-07-22 | Form 4 | 2026-07-24 | 0001193125-26-315240 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 41 | Section 06, 2026 vote | Form 8-K | 2026-06-18 | 0001104659-26-075720 | Item 5.07 · say-on-pay result. As reported: 96.24% (votes for as printed: 158,547,441). Filing ↗ |
| 42 | Section 06, 2025 vote | Form 8-K | 2025-06-25 | 0001104659-25-062576 | Item 5.07 · say-on-pay result. As reported: 85.68% (votes for as printed: 115,026,066). Filing ↗ |
| 43 | Section 03b vehicle mix (computed) | Computed | — | computed | RSU / PSU / Options grant-date fair values summed per officer from the grants table; % performance-vested = PSU ÷ (RSU+PSU+Options).machine: formula: sums + PSU ratio |
| 44 | Section 09b board cost (computed) | Computed | — | computed | Cash 561,500 + equity 0 + all other 0 = 561,500, summed across the director compensation table rows.machine: formula: Σ = 561,500 |
| 45 | Element, Section 10b CEO total | DEF 14A | 2026-03-23 | 0001590714-26-000034 | CEO total compensation as printed in Element's own proxy. As printed: 26,480,462. Filing ↗machine: r3 · c27 · span 596335–596345 |
| 46 | Structure Therapeutics (subject), Section 10b CEO total | DEF 14A | 2026-04-23 | 0001104659-26-047740 | CEO total compensation as printed in Structure Therapeutics's own proxy. As printed: 8,429,887. Filing ↗machine: r1 · c47 · span 552927–552936 |
| 47 | Section 10a, Element reciprocity | DEF 14A | — | 0001590714-26-000034 | Element's most recent proxy was read; its disclosed peer group does not include Structure Therapeutics. Filing ↗ |